Log In
BCIQ
Print this Print this
 

Dyanavel XR, amphetamine

  Manage Alerts
Collapse Summary General Information
Company Tris Pharma Inc.
DescriptionOnce-daily, extended-release liquid formulation of amphetamine developed using LiquiXR technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat ADHD
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today